General Information of Drug (ID: DMASO86)

Drug Name
4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
Synonyms
CHEMBL1086903; 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide; MLS000532882; AC1LQXAP; CBMicro_028883; Oprea1_410069; Oprea1_118265; MolPort-001-490-660; HMS2484B06; STK413461; ZINC13468414; BDBM50312579; AKOS003253125; MCULE-2070823146; SMR000140320; BIM-0028795.P001; ST50914634; N-cyclohexyl-4-(diphenylmethyl)piperazine-1-carboxamide; N-cyclohexyl-4-(diphenylmethyl)-1-piperazinecarboxamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 377.5
Logarithm of the Partition Coefficient (xlogp) 4.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C24H31N3O
IUPAC Name
4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
Canonical SMILES
C1CCC(CC1)NC(=O)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChI=1S/C24H31N3O/c28-24(25-22-14-8-3-9-15-22)27-18-16-26(17-19-27)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23H,3,8-9,14-19H2,(H,25,28)
InChIKey
IRRGBCHOFRYUCB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1358608
CAS Number
401578-04-9
TTD ID
D04ICJ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cannabinoid receptor 1 (CB1) DTT CNR1 5.59E-02 -0.22 -0.45
Cannabinoid receptor 1 (CB1) DTT CNR1 7.68E-01 -0.06 -0.46
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.